Adaptive Biotechnologies (ADPT) Depreciation & Amortization (CF) (2024 - 2026)

Adaptive Biotechnologies has disclosed Depreciation & Amortization (CF) across 3 years of filings, most recently posting $3.2 million for Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) fell 20.54% year-over-year to $3.2 million; the TTM figure through Jun 2026 stood at $14.2 million (down 13.37% YoY), while the FY2025 annual figure was $16.0 million, down 8.26% from the prior year.
• Depreciation & Amortization (CF) came in at $3.2 million for Q2 2026 at Adaptive Biotechnologies, down from $3.4 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.2 million in Q1 2024 to a low of $3.2 million in Q2 2026.
• Average Depreciation & Amortization (CF) over 3 years is $4.0 million, with a median of $4.0 million recorded in 2025.
• Year-over-year, Depreciation & Amortization (CF) retreated 4.43% in 2025 and fell 21.0% in 2026.
• Over 3 years, Depreciation & Amortization (CF) stood at $3.9 million in 2024, then decreased by 7.1% to $3.7 million in 2025, then slipped by 11.42% to $3.2 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $3.2 million in Q2 2026, $3.4 million in Q1 2026, and $3.7 million in Q4 2025.